Forum on Regenerative Medicine
The Forum on Regenerative Medicine provides a convening mechanism for interested parties from academia, industry, government, patient and provider organizations, regulators, foundations, and others to engage in discussions that address the challenges facing the application of, and the opportunities for, regenerative medicine to improve health through the development of effective new therapies. The Forum identifies potential barriers to scientific advances; examines the impact of current policies on discovery, development, and translation of regenerative medicine therapies; considers unique challenges of identifying, validating, and bringing regenerative medicine applications to market; and explores ethical, legal, and social issues posed by regenerative medicine advances.
In progress
Any project, supported or not by a committee, that is currently being worked on or is considered active, and will have an end date.
"We convene a variety of interested parties to spark exchange and inspire action to advance regenerative medicine for the benefit of all."
The forum’s Clinical Translation and Implementation working group considers the obstacles and opportunities to improve clinical translation, implementation, and access to regenerative medicine therapies for all. Through their activities, this working group aims to highlight the perspectives of patients, clinicians, and payers in the clinical translation and implementation of cell, gene, and tissue-based therapies.
Examples of forum activities:
• The Intersection of Regenerative Medicine and Women’s Health: A Workshop
• Understanding the Role of the Immune System in Improving Tissue Regeneration: A Workshop
• Exploring Novel Clinical Trial Designs for Gene-Based Therapies: A Workshop
The forum’s Innovation and Emerging Technologies working group aims to explore the innovations and emerging technologies that enable the development and delivery of safe and effective regenerative medicine products to patients faster, at scale, and more efficiently.
Examples of forum activities:
• Developing Regenerative Medicine Therapies with Artificial Intelligence: A Workshop
• Emerging Technologies and Innovation in Manufacturing Regenerative Medicine Therapies: A Workshop
• Applying Systems Thinking to Regenerative Medicine: A Workshop
The forum’s Workforce Development working group examines incentives and disincentives for the expansion and retention of the regenerative medicine workforce. Members examine the increasingly interdisciplinary nature of the field of regenerative medicine to better understand gaps in training and development for creating a workforce that is knowledgeable in data science, mathematics, modelling, and informatics.
Example of forum activity:
• Training the Regenerative Medicine Workforce for the Future: A Workshop
The forum’s Core Group consists of co-leads from each of the working groups. In alignment with the forum’s purpose and strategic plan, the group coordinates activities across the forum, identifies topics and speakers of interest for upcoming forum meetings, and monitors scientific and technological advancements in regenerative medicine and develops sessions on updates in policies and ethics surrounding the field. They also stay abreast of current regulatory developments, including standards and the roles of various regulatory bodies in enforcing regulations and policies related to regenerative medicine products, policy changes, and issues related to cost of therapies.
Examples:
• In 2019, Google released a new advertising policy to describe a category of "speculative and experimental medical treatments." Google's decision to explore its advertising policy was informed by its participation in the forum's February 2019 meeting and subsequently through individual follow-up discussions with several forum members.
Our mission
The work of the forum engages interested parties to explore:
existing and potential barriers to scientific and therapeutic advances;
the impact of current policies on the discovery, development, and translation of regenerative medicine therapies;
the challenges of identifying, validating, and bringing regenerative medicine applications to market;
and the ethical, legal, and social issues posed by regenerative medicine advances.
Forum activities—including public workshops, membership meetings, and other information-gathering activities—provide opportunities to discuss important questions and challenges in the field of regenerative medicine and foster the advancement of high-quality science toward safe and effective therapies for patients.
The forum membership includes leaders from government, academia, pharmaceutical and biotechnology companies, professional groups and associations, and patient advocacy organizations. Forum members work together to illuminate critical issues and challenges facing the application of, and the opportunities for, regenerative medicine to improve health through the development of effective new therapies. View committee.
Forums create communal environments to foster dialogue across sectors and institutions. Although forums do not produce solutions themselves, they illuminate issues that need to be resolved, and opportunities for further work are often developed from meetings, workshops, and publications. For example, the activities of a forum may result in the establishment of a separate consensus study committee. Unlike a consensus study committee, which publishes a report with conclusions and recommendations, a forum may not issue work with such advice.
The forum brings together leaders across federal agencies, the private sector, patient advocacy, and academia, and in doing so, serves to help advance the field and facilitate the discovery, development, and translation of regenerative medicine findings into therapies.
Contact us to learn more about how to engage with the forum:
Description
The Institute of Medicine’s Board on Health Sciences Policy and the National Research Council's Board on Life Sciences will establish a Forum on Regenerative Medicine. The purpose of the Forum is to explore strategies for advancing the field of regenerative medicine and facilitating the discovery, development, and translation of regenerative medicine findings into therapies for medicine, public health initiatives, education, and policy. The Forum will bring together leaders from academia, industry, government, patient and provider organizations, regulators, payers, and foundations to engage in dialogue and discussions that address the challenges facing the application of and the opportunities for regenerative medicine to advance public health. The Forum will identify existing and potential barriers to scientific and therapeutic advances; identify and discuss opportunities to assist in facilitating more effective partnerships among key stakeholders; examine the impact that current policies have on the discovery, development, and translation of regenerative medicine therapies; examine the unique challenges of identifying, validating, and bringing regenerative medicine applications to market; and explore the ethical, legal, and social issues posed by regenerative medicine advances. The Forum membership will determine agenda topics, which will likely span a broad range of issues, and use public workshops, discussions, and commissioned papers to inform its future activities. All activities of the Forum will be conducted in accordance with institutional guidelines described in "Roundtables: Policy and Procedures."
Collaborators
Committee
Krishnendu Roy
Co-Chair
Katherine Tsokas
Co-Chair
Ginny Beakes-Read
Ex Officio Member
Tammy R.L. Collins
Ex Officio Member
Uta Grieshammer
Ex Officio Member
Albert Hwa
Ex Officio Member
Aron Marquitz
Ex Officio Member
Michael H. May
Ex Officio Member
Richard McFarland
Ex Officio Member
Jack Mosher
Ex Officio Member
Lisa A. Neuhold
Ex Officio Member
Amy Patterson
Ex Officio Member
Thomas Petersen
Ex Officio Member
Kimberlee Potter
Ex Officio Member
David Rampulla
Ex Officio Member
Derek Robertson
Ex Officio Member
Derrick Rossi
Ex Officio Member
Nabiha Saklayen
Ex Officio Member
Rachel Salzman
Ex Officio Member
Sumona Sarkar
Ex Officio Member
Eric Sid
Ex Officio Member
Scott Steele
Ex Officio Member
Fei Wang
Ex Officio Member
Daniel Weiss
Ex Officio Member
Michael Werner
Ex Officio Member
Kathleen Zackowski
Ex Officio Member
Karen Christman
Member-at-Large
Constance Chu
Member-at-Large
Cato T. Laurencin
Member-at-Large
Erika Moore
Member-at-Large
Krishanu Saha
Member-at-Large
Jessica Weaver
Member-at-Large
Sponsors
Advanced Regenerative Manufacturing Institute
Alliance for Regenerative Medicine
American Society of Gene & Cell Therapy
Burroughs Wellcome Fund
California Institute for Regenerative Medicine
Cellino
Centre for Commercialization of Regenerative Medicine
Department of Veterans Affairs
Food and Drug Administration
International Society for Cellular Therapy
International Society for Stem Cell Research
Johnson & Johnson
National Institute of Standards and Technology
National Institutes of Health
New York Stem Cell Foundation
United Therapeutics